Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when combined with diet and exercise. GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jazeta, a DPP‑4 inhibitor, is employed in the treatment of type 2 diabetes and related glycaemic control pathways. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels as part of a comprehensive regimen. - Monotherapy in type 2 diabetes: reduces HbA1c when used alone in patients inadequately controlled by lifestyle alone. - Combination therapy with metformin: enhances overall glycaemic control when added to metformin‑based regimens.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate head pain. - Upper respiratory tract infection: cough, sore throat, or congestion. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Bullous pemphigoid: rare skin blistering disorder. - Hepatic injury: abnormal liver function tests or jaundice.

Before initiating therapy, consider the following safety measures. - Renal function: assess creatinine clearance and adjust dose in impaired patients. - Cardiovascular disease: monitor for signs of heart failure, especially in high‑risk individuals. - Hypersensitivity: discontinue immediately if allergic reactions occur. - Elderly patients: start at the lowest effective dose and titrate cautiously. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Sitagliptin may interact with several medicines; review concomitant therapy. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Insulin: combined use can raise hypoglycaemia risk. - Sulfonylureas: heightened risk of low blood glucose.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin effectiveness. - Diuretics: potential alteration of glucose control. - ACE inhibitors: monitor renal function when used together.